Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MP-101 Open Label Extension in Short Bowel Syndrome
NCT02246816Phase 3Withdrawn
- Sponsor
- Marathon Pharmaceuticals
- Start
- Feb 2015
- Primary completion
- Feb 2018
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of opium tincture in short bowel syndrome (SBS), sponsored by Marathon Pharmaceuticals. Primary endpoint: Number of Participants with Adverse Events up to 120 Days. Planned start Feb 2015; status: withdrawn.
02
Drugs
opium tincture
03
Conditions
short bowel syndrome (SBS)
Beyond the preview
Go deeper on NCT02246816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02246816.